| pubmed-article:3764442 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3764442 | lifeskim:mentions | umls-concept:C0004927 | lld:lifeskim |
| pubmed-article:3764442 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:3764442 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
| pubmed-article:3764442 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:3764442 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:3764442 | pubmed:issue | 3 Suppl 2 | lld:pubmed |
| pubmed-article:3764442 | pubmed:dateCreated | 1986-11-7 | lld:pubmed |
| pubmed-article:3764442 | pubmed:abstractText | A human tumor cloning system was utilized to screen for the antitumor activity of recombinant interferon alfa-2b (Intron A) alone and in combination with standard antineoplastic agents. These in vitro studies confirmed synergistic effects of alfa-2b plus doxorubicin against primary human tumors. Based on those in vitro findings, a phase I study has been conducted by Sarosy and colleagues that demonstrated that recombinant interferon alpha-2b and doxorubicin could be given together. Myelosuppression was the dose-limiting toxicity. Because responses were noted in the phase I trials with the combination, phase II trials of the combination are warranted. Additional phase I studies that should be pursued include recombinant interferon alpha-2b plus 5-fluorouracil, interferon plus cisplatinum, and interferon plus DTIC. | lld:pubmed |
| pubmed-article:3764442 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3764442 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3764442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3764442 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3764442 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3764442 | pubmed:issn | 0093-7754 | lld:pubmed |
| pubmed-article:3764442 | pubmed:author | pubmed-author:BrownT DTD | lld:pubmed |
| pubmed-article:3764442 | pubmed:author | pubmed-author:Von HoffD DDD | lld:pubmed |
| pubmed-article:3764442 | pubmed:author | pubmed-author:KuhnJ GJG | lld:pubmed |
| pubmed-article:3764442 | pubmed:author | pubmed-author:KisnerD LDL | lld:pubmed |
| pubmed-article:3764442 | pubmed:author | pubmed-author:SarosyGG | lld:pubmed |
| pubmed-article:3764442 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3764442 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:3764442 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3764442 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3764442 | pubmed:pagination | 72-7 | lld:pubmed |
| pubmed-article:3764442 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:meshHeading | pubmed-meshheading:3764442-... | lld:pubmed |
| pubmed-article:3764442 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3764442 | pubmed:articleTitle | Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin. | lld:pubmed |
| pubmed-article:3764442 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3764442 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3764442 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:3764442 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
